95 related articles for article (PubMed ID: 3455156)
1. Paget's disease of bone treated in five days with AHPrBP (APD) per Os.
Thiébaud D; Jaeger P; Burckhardt P
J Bone Miner Res; 1987 Feb; 2(1):45-52. PubMed ID: 3455156
[TBL] [Abstract][Full Text] [Related]
2. A single infusion of the bisphosphonate AHPrBP (APD) as treatment of Paget's disease of bone.
Thiébaud D; Jaeger P; Gobelet C; Jacquet AF; Burckhardt P
Am J Med; 1988 Aug; 85(2):207-12. PubMed ID: 3261129
[TBL] [Abstract][Full Text] [Related]
3. A single infusion of bisphosphonate AHPrBP in the treatment of Paget's disease of bone.
Chakravarty K; Merry P; Scott DG
J Rheumatol; 1994 Nov; 21(11):2118-21. PubMed ID: 7869320
[TBL] [Abstract][Full Text] [Related]
4. [Paget's disease of bone treated per os with APD in 5 days].
Thiébaud D; Jaeger P; Burckhardt P
Schweiz Med Wochenschr; 1986 Dec; 116(50):1787-9. PubMed ID: 3798071
[TBL] [Abstract][Full Text] [Related]
5. [A single infusion of Pamidronate (APD) in Paget's disease of bone].
Thiébaud D; Jaeger P; Jacquet AF; Burckhardt P
Schweiz Med Wochenschr; 1989 Jan; 119(3):71-4. PubMed ID: 2711157
[TBL] [Abstract][Full Text] [Related]
6. Intravenous aminopropylidene bisphosphonate (APD) in the treatment of Paget's bone disease.
Vega E; Gonzalez D; Ghiringhelli G; Mautalen C
J Bone Miner Res; 1987 Aug; 2(4):267-71. PubMed ID: 3455613
[TBL] [Abstract][Full Text] [Related]
7. Sustained biochemical effects of short treatment of Paget's disease of bone with dichloromethylene diphosphonate.
Chapuy MC; Charhon SA; Meunier PJ
Metab Bone Dis Relat Res; 1983; 4(6):325-8. PubMed ID: 6229683
[TBL] [Abstract][Full Text] [Related]
8. Determinants of remission of Paget's disease of bone.
Patel S; Stone MD; Coupland C; Hosking DJ
J Bone Miner Res; 1993 Dec; 8(12):1467-73. PubMed ID: 8304048
[TBL] [Abstract][Full Text] [Related]
9. Aminohexane diphosphonate in the treatment of Paget's disease of bone.
Atkins RM; Yates AJ; Gray RE; Urwin GH; Hamdy NA; Beneton MN; Rosini S; Kanis JA
J Bone Miner Res; 1987 Aug; 2(4):273-9. PubMed ID: 3455614
[TBL] [Abstract][Full Text] [Related]
10. Effects of five daily 1 h infusions of alendronate in Paget's disease of bone.
O'Doherty DP; Gertz BJ; Tindale W; Sciberras DG; Survill TT; Kanis JA
J Bone Miner Res; 1992 Jan; 7(1):81-7. PubMed ID: 1549961
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Paget's disease of bone with aminohydroxybutylidene bisphosphonate.
O'Doherty DP; Bickerstaff DR; McCloskey EV; Hamdy NA; Beneton MN; Harris S; Mian M; Kanis JA
J Bone Miner Res; 1990 May; 5(5):483-91. PubMed ID: 2195845
[TBL] [Abstract][Full Text] [Related]
12. Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment.
Alvarez L; Peris P; Guañabens N; Vidal S; Quintó L; Monegal A; Pons F; Ballesta AM; Muñoz-Gómez J
Rheumatology (Oxford); 2004 Jul; 43(7):869-74. PubMed ID: 15054158
[TBL] [Abstract][Full Text] [Related]
13. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease.
Garnero P; Gineyts E; Schaffer AV; Seaman J; Delmas PD
Arthritis Rheum; 1998 Feb; 41(2):354-60. PubMed ID: 9485094
[TBL] [Abstract][Full Text] [Related]
14. Treatment of Paget's disease with intermittent low-dose infusions of disodium pamidronate (APD).
Stone MD; Hawthorne AB; Kerr D; Webster G; Hosking DJ
J Bone Miner Res; 1990 Dec; 5(12):1231-5. PubMed ID: 2075835
[TBL] [Abstract][Full Text] [Related]
15. The effects of intravenous alendronate in Paget's disease of bone.
O'Doherty DP; McCloskey EV; Vasikaran S; Khan S; Kanis JA
J Bone Miner Res; 1995 Jul; 10(7):1094-100. PubMed ID: 7484285
[TBL] [Abstract][Full Text] [Related]
16. Rapid, divergent changes in spinal and forearm bone density following short-term intravenous treatment of Paget's disease with pamidronate disodium.
Price RI; Gutteridge DH; Stuckey BG; Kent GN; Retallack RW; Prince RL; Bhagat CI; Johnston CA; Nicholson GC; Stewart GO
J Bone Miner Res; 1993 Feb; 8(2):209-17. PubMed ID: 8442439
[TBL] [Abstract][Full Text] [Related]
17. [Factors that determine intensity of response to treatment with tiludronate in Paget's disease].
Morales Piga A; Abraira Santos V; Rey Rey JS; de Abajo Iglesias F
Med Clin (Barc); 1998 Feb; 110(7):254-8. PubMed ID: 9562949
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of a new formulation of oral tiludronate (tablet) in the treatment of Paget's disease of bone.
Reginster JY; Treves R; Renier JC; Amor B; Sany J; Ethgen D; Picot C; Franchimont P
J Bone Miner Res; 1994 May; 9(5):615-9. PubMed ID: 8053389
[TBL] [Abstract][Full Text] [Related]
19. Paget's disease of bone: experience from a centre in southern India.
Anjali ; Thomas N; Rajaratnam S; Shanthly N; Oommen R; Seshadri MS
J Assoc Physicians India; 2006 Jul; 54():525-9. PubMed ID: 17089899
[TBL] [Abstract][Full Text] [Related]
20. Long-term elevation of 1,25-dihydroxyvitamin D after short-term intravenous administration of pamidronate (aminohydroxypropylidene bisphosphonate, APD) in Paget's disease of bone.
Devlin RD; Retallack RW; Fenton AJ; Grill V; Gutteridge DH; Kent GN; Prince RL; Worth GK
J Bone Miner Res; 1994 Jan; 9(1):81-5. PubMed ID: 8154313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
